Skip to main content
Clinical Trials/NCT06478160
NCT06478160RecruitingNot Applicable

Effectiveness of Closed-blood Sampling Devices in the Adult Critically Ill Patient: Multicenter Randomized Clinical Trial

University of Barcelona3 sites in 1 country216 target enrollmentStarted: November 11, 2024Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Enrollment
216
Locations
3
Primary Endpoint
Units of red blood cells transfusion

Study Overview

Brief Summary

Based on the hypothesis that the strategy of using Closed-Blood Sampling Devices (CSBD, experimental group) compared to the usual practice (waste discard volume, control group), in critically ill adult patients, will decrease the amount of blood withdrawn for laboratory tests, we want to analyze the number of red blood cells (RBC) administered and arterial catheter-related adverse events (catheter-related bacteremia, catheter obstruction, CBSD malfunction, loss of arterial pressure waveform on the patient's bedside monitor) in both study groups, during ICU stay and up to a maximum of 21 days.

Detailed Description

When a patient with an arterial catheter completes 24h of admission to the unit, with an expected catheter stay of more than 72 hours, inclusion in the study will be assessed. If the patient does not meet the non-inclusion or exclusion criteria and consents to participate in the study, he/she will be randomized to the CBSD-experimental group or waste discard volume- control group.

If the patient belongs to the CBSD-experimental group, the CBSD will be placed in the arterial line at that moment. All extractions performed will be through the arterial catheter and using the CBSD.

In the waste discard volume- control group, the arterial catheter will also be used for extractions but with the usual open extraction system of the ICU. To quantify the blood loss related to blood collection for laboratory tests, the volume of discharge (VD) used for each analysis through the arterial catheter will be recorded. In the CBSD-experimental group the VD for arterial catheter will be zero since CBSD will always be used. The laboratory tubes extracted in each analysis will also be recorded.

Data on blood analysis, blood transfusion and adverse events related to the arterial catheter will be recorded daily during the ICU stay, up to day 21 maximum and/or day of ICU discharge and/or exitus.

Patients discharged from ICU to hospitalization will be followed only during the first 48h to know if they have received red blood cell concentrates and with what previous Hemoglobine (Hb) and hematocrit (Hto).

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Double (Investigator, Outcomes Assessor)

Masking Description

Outcomes Assessor and statistician who analyze the results

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Adult patients with an arterial catheter who agree to participate in the study, with a stay in the ICU of 24h and a minimum of 72h more with an arterial catheter
  • •Non-inclusion criteria: Therapeutic Limitation of Life Support, Jehovah's Witnesses.

Exclusion Criteria

  • •Patients with chronic renal failure
  • •Patients with active gastrointestinal bleeding
  • •Patients diagnosed with hematologic cancer
  • •Women with menstruation at the time of admission
  • •Pregnant women
  • •Withdrawal criteria: presence of active gastrointestinal bleeding during the study inclusion period.

Arms & Interventions

CBSD-experimental group

Experimental

blood collection with Closed-Blood Sampling System (CBSD)

Intervention: Closed-Blood Sampling Devices (Device)

Waste discard volume, control group

Active Comparator

Blood collection without CBSD, usual practice, need to waste discard volume

Intervention: Waste discard volume (Other)

Outcomes

Primary Outcomes

Units of red blood cells transfusion

Time Frame: Every day during the ICU stay and up to a maximum of 21 days after randomization (day 0)

Number of red blood cells (RBC) units administered in both study groups

Secondary Outcomes

  • Number and type of adverse events(Every day during the stay and up to a maximum of 21 days after randomization (day 0):)
  • Volume of blood drawn(Every day during ICU stay and up to a maximum of 21 days after randomization (day 0).)
  • Levels of hemoglobine and hematocrit(Every day during ICU stay and up to a maximum of 21 days after randomization (day 0).)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Marta Raurell-Torreda

Clinical Professor

University of Barcelona

Study Sites (3)

Loading locations...

Similar Trials